Larimar Therapeutics Enters Material Definitive Agreement
Ticker: LRMR · Form: 8-K · Filed: Feb 16, 2024 · CIK: 1374690
| Field | Detail |
|---|---|
| Company | Larimar Therapeutics, Inc. (LRMR) |
| Form Type | 8-K |
| Filed Date | Feb 16, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $8.74, $161.8 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-event
TL;DR
**Larimar Therapeutics just inked a major deal, expect potential shifts in their business!**
AI Summary
Larimar Therapeutics, Inc. filed an 8-K on February 16, 2024, reporting an "Entry into a Material Definitive Agreement" on February 14, 2024. The filing indicates a significant new agreement for the company, which operates under the SIC code for Pharmaceutical Preparations. This agreement is likely to impact the company's future operations and financial standing.
Why It Matters
This filing signals a new, potentially impactful agreement for Larimar Therapeutics, which could influence its strategic direction, financial health, and drug development efforts.
Risk Assessment
Risk Level: medium — The filing indicates a material agreement without disclosing details, creating uncertainty about its specific impact, which could be positive or negative.
Key Players & Entities
- Larimar Therapeutics, Inc. (company) — Registrant
- ZAFGEN, INC. (company) — Former Company Name
- February 14, 2024 (date) — Date of earliest event reported
- February 16, 2024 (date) — Filing date
- 001-36510 (other) — Commission File Number
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 14, 2024.
What is the primary item information disclosed in this 8-K?
The primary item information disclosed is "Entry into a Material Definitive Agreement" and "Financial Statements and Exhibits."
What is the SIC code for Larimar Therapeutics, Inc.?
Larimar Therapeutics, Inc.'s Standard Industrial Classification (SIC) is PHARMACEUTICAL PREPARATIONS [2834].
What was the former name of Larimar Therapeutics, Inc.?
Larimar Therapeutics, Inc. was formerly known as ZAFGEN, INC. and ZAFGEN INC.
When was this 8-K filed with the SEC?
This 8-K was filed with the SEC on February 16, 2024.
Filing Stats: 881 words · 4 min read · ~3 pages · Grade level 11.2 · Accepted 2024-02-16 16:06:02
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share LRMR Nasdaq Global Market
- $8.74 — e Company at a public offering price of $8.74 per share, less the underwriting discou
- $161.8 m — ny from the Offering were approximately $161.8 million, after deducting underwriting dis
Filing Documents
- d780024d8k.htm (8-K) — 29KB
- d780024dex11.htm (EX-1.1) — 231KB
- d780024dex51.htm (EX-5.1) — 8KB
- g780024g0215083623153.jpg (GRAPHIC) — 3KB
- 0001193125-24-038473.txt ( ) — 456KB
- lrmr-20240214.xsd (EX-101.SCH) — 3KB
- lrmr-20240214_lab.xml (EX-101.LAB) — 18KB
- lrmr-20240214_pre.xml (EX-101.PRE) — 11KB
- d780024d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Below is a list of exhibits included with this Current Report on Form 8-K. Exhibit No. Document 1.1 Underwriting Agreement, dated February 14, 2024, by and among the Company, Leerink Partners LLC, Citigroup Global Markets Inc. and Guggenheim Securities, LLC, as representatives of the several underwriters named therin* 5.1 Opinion of Goodwin Procter LLP* 23.1 Consent of Goodwin Procter LLP (included in Exhibit 5.1)* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Larimar Therapeutics, Inc. By: /s/ Carole S. Ben-Maimon, M.D. Name: Carole S. Ben-Maimon, M.D. Title: President and Chief Executive Officer Date: February 16, 2024